These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37513756)

  • 1. Analysis of Discordance between Genotypic and Phenotypic Assays for Rifampicin-Resistant
    Bokop C; Faye LM; Apalata T
    Pathogens; 2023 Jul; 12(7):. PubMed ID: 37513756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xpert MTB/RIF for rapid detection of rifampicin-resistant Mycobacterium tuberculosis from pulmonary tuberculosis patients in Southwest Ethiopia.
    Tadesse M; Aragaw D; Dimah B; Efa F; Abebe G
    Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S48-S49. PubMed ID: 28043605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discordant results between Xpert MTB/RIF assay and Bactec MGIT 960 culture system regarding the detection of rifampin-resistant
    He G; Zheng Q; Wu J; Wu L; Geng Z; Jiang G; Huang H; Jiang X; Yu X
    Microbiol Spectr; 2024 Jun; 12(6):e0385923. PubMed ID: 38738892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Line probe assay test in new cases of tuberculosis with rifampicin resistance not detected by Xpert MTB/RIF.
    Soedarsono S; Mertaniasih NM; Hasan H; Kusmiati T; Permatasari A; Kusumaningrum D; Wijaksono W
    Int J Mycobacteriol; 2022; 11(4):429-434. PubMed ID: 36510930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant Mycobacterium tuberculosis.
    Rufai SB; Kumar P; Singh A; Prajapati S; Balooni V; Singh S
    J Clin Microbiol; 2014 Jun; 52(6):1846-52. PubMed ID: 24648554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordance between genotypic and phenotypic methods for the detection of rifampicin and isoniazid resistant
    Bonsa Z; Tadesse M; Balay G; Kebede W; Abebe G
    J Clin Tuberc Other Mycobact Dis; 2024 Feb; 34():100410. PubMed ID: 38225941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Performance of Line Probe Assay (Version 2) and Xpert MTB/RIF Assay for Early Diagnosis of Rifampicin-Resistant Pulmonary Tuberculosis.
    Yadav RN; Kumar Singh B; Sharma R; Chaubey J; Sinha S; Jorwal P
    Tuberc Respir Dis (Seoul); 2021 Jul; 84(3):237-244. PubMed ID: 33657709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparing performance of "TB-BIOCHIP", "Xpert MTB/RIF" and "genotype MTBDRplus" assays for fast identification of mutations in the Mycobacterium tuberculosis complex in sputum from TB patients].
    Nosova EIu; Krasnova MA; Galkina KIu; Makarova MV; Litvinov VI; Moroz AM
    Mol Biol (Mosk); 2013; 47(2):267-74. PubMed ID: 23808160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-Resistant Tuberculosis on the Balkan Peninsula: Determination of Drug Resistance Mechanisms with Xpert MTB/XDR and Whole-Genome Sequencing Analysis.
    Truden S; Sodja E; Žolnir-Dovč M
    Microbiol Spectr; 2023 Mar; 11(2):e0276122. PubMed ID: 36877052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of false-positive rifampicin resistance on the Xpert MTB/RIF.
    Cayci YT; Bilgin K; Coban AY; Birinci A; Durupınar B
    Mem Inst Oswaldo Cruz; 2017 Nov; 112(11):756-759. PubMed ID: 29091135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discordant results between genotypic and phenotypic assays (Xpert MTB/RIF vs. BACTEC MGIT 960 system) for detection of RIF-resistant Mycobacterium tuberculosis isolates in a high burden region.
    Rafael LL; Raquel MS; Rogelio FA; Miroslava FP; Alejandra-Isabel JG; Paola RS
    Infect Genet Evol; 2021 Dec; 96():105142. PubMed ID: 34800711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Xpert MTB/XDR test for susceptibility testing of Mycobacterium tuberculosis to first and second-line drugs in Uganda.
    Katamba A; Ssengooba W; Sserubiri J; Semugenze D; Kasule GW; Nyombi A; Byaruhanga R; Turyahabwe S; Joloba ML
    PLoS One; 2023; 18(8):e0284545. PubMed ID: 37590288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Xpert
    Katamba A; Ssengooba W; Sserubiri J; Semugenze D; William KG; Abdunoor N; Byaruhanga R; Turyahabwe S; Joloba ML
    medRxiv; 2023 Apr; ():. PubMed ID: 37066316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic screening for drug-resistant tuberculosis with Xpert(®) MTB/RIF in a referral hospital in Cambodia.
    Lorent N; Kong C; Kim T; Sam S; Thai S; Colebunders R; Rigouts L; Lynen L
    Int J Tuberc Lung Dis; 2015 Dec; 19(12):1528-35. PubMed ID: 26614197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of the REBA MTB-Rifa® assay for rapid detection of rifampicin resistant Mycobacterium tuberculosis.
    Cho E; Shamputa IC; Kwak HK; Lee J; Lee M; Hwang S; Jeon D; Kim CT; Cho S; Via LE; Barry CE; Lee JS
    BMC Infect Dis; 2013 Oct; 13():478. PubMed ID: 24128118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitigation of Discordant Rifampicin-Susceptibility Results Obtained by Xpert Mycobacterium tuberculosis/Rifampicin and Mycobacterium Growth Indicator Tube.
    Gurbanova E; Mehdiyev R; Blondal K; Tahirli R; Mirzayev F; Hillemann D; Ismayilov A; Altraja A
    Microb Drug Resist; 2017 Dec; 23(8):1045-1052. PubMed ID: 28447869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Performance of the Abbott Real Time MTB RIF/INH Compared to the MTBDR
    David A; Singh L; Da Silva P; Scott L; Stevens W
    Infect Drug Resist; 2020; 13():3301-3308. PubMed ID: 33061477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of Cepheid ® Xpert MTB/RIF ® and TB-Biochip ® MDR in two regions of Russia with a high prevalence of drug-resistant tuberculosis.
    Kurbatova EV; Kaminski DA; Erokhin VV; Volchenkov GV; Andreevskaya SN; Chernousova LN; Demikhova OV; Ershova JV; Kaunetis NV; Kuznetsova TA; Larionova EE; Smirnova TG; Somova TR; Vasilieva IA; Vorobieva AV; Zolkina SS; Cegielski JP
    Eur J Clin Microbiol Infect Dis; 2013 Jun; 32(6):735-43. PubMed ID: 23263819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa.
    Maningi NE; Malinga LA; Antiabong JF; Lekalakala RM; Mbelle NM
    BMC Infect Dis; 2017 Dec; 17(1):795. PubMed ID: 29282012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Evaluation of a Line-Probe Assay for Tuberculosis Detection and Drug-Resistance Prediction in Namibia.
    Günther G; Saathoff E; Rachow A; Ekandjo H; Diergaardt A; Marais N; Lange C; Nepolo E
    Microbiol Spectr; 2022 Jun; 10(3):e0025922. PubMed ID: 35670620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.